Form 4: Leap Therapeutics CEO Douglas Onsi Acquires 170,000 Stock Options
SEC Form 4 Filing
Douglas Onsi, CEO, CFO, President, General Counsel, Treasurer, and Secretary of Leap Therapeutics, Inc., was granted 170,000 employee stock options on October 2, 2024.
Summary
- This Form 4 filing reports a change in beneficial ownership of securities of Leap Therapeutics, Inc. by Douglas E. Onsi, who holds multiple executive positions within the company.
- On October 2, 2024, Onsi was granted 170,000 employee stock options with an exercise price of $2.45.
- These options vest in 36 equal monthly installments, starting one month after the grant date, contingent upon continued service to the company.
- Following this transaction, Onsi directly owns 170,000 derivative securities (employee stock options).
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and suggests confidence in the company's future performance. However, it's not a major event that would drastically alter the company's outlook.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The size and terms of the grant are typical for executives in similar roles at comparable companies.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
- The vesting schedule of 36 months is also a common practice to ensure long-term commitment.
Stakeholder Impact
- Shareholders may view the option grant positively as it aligns management's interests with theirs.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 10/02/2024 | Date of earliest transaction: Grant of 170,000 employee stock options. |
| 10/02/2024 | Option grant date and first vesting date. |
| 10/04/2024 | Date of signature. |
| 10/02/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.